Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy

Open access

Abstract

INTRODUCTION: Both glucagon-like peptide-1 receptor agonists (GLP-1 RA) and continuous glucose monitoring (CGM) improve glycemia in patients with type 2 diabetes (T2D). However, it is unknown whether adding CGM to GLP-1 RA therapy further improves A1c. We evaluated changes in A1c levels 6 months after initiation of FreeStyle Libre (FSL) in adults with sub-optimally controlled T2D already on GLP-1 RA therapy. METHODS: This retrospective, observational study used Optum's de-identified Market Clarity Data, a linked electronic health record-claims database to assess changes in A1c after FSL acquisition. Inclusion criteria were T2D diagnosis, ≥ 18 years, baseline A1c ≥ 8%, with the first FSL acquisition between 2018 and 2022. Patients were required to be on GLP-1 RA prior to FSL with at least one GLP-1 RA prescription within 90 days of FSL acquisition. GLP-1 RA initiation was defined as the earliest GLP-1 RA prescription from 2017 onwards. Paired changes in A1c were assessed at 6 months after initial FSL acquisition. RESULTS: The study cohort included 1454 adults with T2D (age 55 ± 10 years, 52% male, 38% with intensive insulin therapy, median 471 days from GLP-1 RA initiation to FSL, and baseline A1c 9.8 ± 1.5%). After FSL acquisition, patients experienced an A1c decrease of 1.5 ± 1.9% (p < 0.001). Patients with a baseline A1c > 10% had the largest reduction (n = 497, - 2.7 ± 2.2%, p < 0.001). Significant improvements were observed in subgroups based on insulin therapy and GLP-1 RA formulation. Those initiating GLP-1 RA therapy > 24 months before FSL acquisition also showed improvements in A1c (n = 478; - 1.3 ± 1.7%, p < 0.001). CONCLUSIONS: In a large, real-world study of adults with T2D, those on prior GLP-1 RA therapy experienced significant A1c improvements after acquiring FSL, irrespective of GLP-1 RA duration, GLP-1 RA formulation, or insulin therapy type. These findings support the use of FSL in adults with T2D treated with GLP-1 RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-024-01619-1

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Baseline and follow-up A1c measurements. T time in days
Fig. 1 Baseline and follow-up A1c measurements. T time in daysCC BY-NC · PubMed Central
Fig. 2 A Changes in A1c for the study cohort. Error bars denote the standard deviation and p < 0.001 for the paired change. B Proportion of individuals with good glycemic control at follow-up. CI confidence interval
Fig. 2 A Changes in A1c for the study cohort. Error bars denote the standard deviation and p < 0.001 for the paired change. B Proportion of individuals with good glycemic control at follow-up. CI confidence intervalCC BY-NC · PubMed Central
Fig. 3 Changes in A1c by insulin therapy. Error bars denote the standard deviation and p < 0.001 for all paired changes. CI confidence intervals
Fig. 3 Changes in A1c by insulin therapy. Error bars denote the standard deviation and p < 0.001 for all paired changes. CI confidence intervalsCC BY-NC · PubMed Central
Fig. 4 Changes in A1c by baseline A1c levels. Error bars denote the standard deviation and p < 0.001 for all paired changes. CI confidence intervals
Fig. 4 Changes in A1c by baseline A1c levels. Error bars denote the standard deviation and p < 0.001 for all paired changes. CI confidence intervalsCC BY-NC · PubMed Central
Fig. 5 Changes in A1c based on A GLP-1 RA duration and B GLP-1 RA formulation. Error bars denote the standard deviation and p < 0.001 for all paired changes. CI confidence intervals, GLP-1 RA glucagon-like peptide-1 receptor agonists
Fig. 5 Changes in A1c based on A GLP-1 RA duration and B GLP-1 RA formulation. Error bars denote the standard deviation and p < 0.001 for all paired changes. CI confidence intervals, GLP-1 RA glucagon-like peptide-1 receptor agonistsCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 9

Metadata

Authors
Miller, E., Chuang, J. S., Roberts, G. J., Nabutovsky, Y., Virdi, N., & Wright, E. E.
Affiliations
  • Abbott (United States) (US)
  • Abbott Diabetes Care (United States) (US)
Corresponding author
Virdi, Naunihal
Venue
Diabetes Therapy
Published
2024-07-15
Volume
15
Issue
9
Pages
2027-2038
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4400657312
Cited by
9
References
35
Citations by year
2026: 5 · 2025: 4
FWCI
2.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Abbott Diabetes Care
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 2 diabetes, continuous glucose monitoring, FreeStyle Libre, GLP-1 receptor agonists, HbA1c, HbA1c reduction, glycemic control, insulin therapy, real-world evidence, treatment initiation timing, intensive insulin therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy. https://app.cochat.ai/papers/10.1007/s13300-024-01619-1
The paper
Miller, E., Chuang, J. S., Roberts, G. J., Nabutovsky, Y., Virdi, N., & Wright, E. E. (2024). Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy. Diabetes Therapy. https://doi.org/10.1007/s13300-024-01619-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.